

Curriculum Vitae	
Univ. Doz. Dr. Hendrik Jan Ankersmit	
Department of Cardio-Thoracic Surgery, General Hospital Vienna, Währinger Gürtel 18-20, A-1090 Vienna hendrik.ankersmit@meduniwien.ac.at	
Personal Data	
Date of Birth:	Jan 12th, 1970
Place of Birth:	Durban, South Africa
Nationality:	Netherlands
Education	
2006	Completion of Cardiac Surgery Fellowship, Board Certified Cardiac Surgeon, Austrian Medical Society
2002	Completion of General Surgery Training, Board Certified Surgeon, Austrian Medical Society
1994	MD
1993	BA, Philosophy, University of Vienna
Career History	
2006 - ongoing	Fellow Thoracic Surgery, Prof. Klepetko
2004	Habilitation in Cardio-Thoracic Surgery
8/2003-8/2006	Cardiac Surgery Fellowship, General Hospital Vienna
Career-related Activities	
6/2003- 7/2003	Scientific Visit, Vascular Research Lab, Dr. AM Schmidt Columbia University, College of Physicians and Surgeons, New York, NY
1/2003 - 7/2003	Department of Anaesthesiology
1/2003 - 7/2003	Post-Doc University Vienna - Boltz-Nitulescu PhD Transplant Immunology
4/1999-5/1999	Scientific Visit, Transplant Immunologie, Dr. Itescu, Columbia University, College of Physicians and Surgeons, New York, NY
11/1996 - 12/1998	Columbia University, College of Physicians and Surgeons, New York, NY (Dr. Robert Michler, Dr.

	Niloo Edwards)		
Awards			
2008	Ernst Wolner Award		
2008	Poster Award, Annual Meeting of the Austrian Society of Pneumology		
2005	AST Young Investigator Award		
2001	AST Young Investigator Award		
2000	ASAIO Fellowship Award		
1999	Young Investigator Award, American Society of Transplant Surgeons		
Memberships			
Austrian Society of Transplantation, Transfusion and Genetics			
Austrian Medical Association			
International Society of Lung and Heart Transplantation			
American Society of Artificial Internal Organs			
Österreichische Gesellschaft für Chirurgie			
Österreichische Gesellschaft für Herz-Thorax Chirurgie			
American Transplant Society			
Sources of funding in last 5 years (2003-2008)			
<i>Period</i>	<i>Organization</i>	<i>Short Title</i>	<i>K€/year</i>
2007 - present	PRIZE, Österreichischen BM für Wirtschaftliche Angelegenheiten	ccCK-18 and AMI	95
2008 - ongoing	APOSCIENCE AG	Unrestricted research grant – 1 residency position (research clinical education)	110
PhD supervision in last 5 years (2003-2008) PhD and master theses for MD			
<i>Period</i>	<i>Name of student</i>	<i>Topic</i>	

2008-	Matthias Zimmermann	Cellular markers in bronchus carcinoma
2008-	Stefanie Nickl	Cellular markers in fibrosis and asthma
2007-	Michael Lichtenauer	Immunology in myocardial infarction
2006-	Andreas Mangold	Alpha-Gal in Valve Surgery
2006-	Tina Niederpold	ST2 protein in CABG patients
2005-	Stefan Hacker	Cellular markers of cell stress in COPD patients
2005-	Konrad Hoetzenecker	CMVIG and apoptosis
2005-2007	Andreas Pollreisz	Intravenous immunoglobulins and aggregation
2002-2003	Markus Brunner	ST2 protein in sepsis and trauma patients
2001-2002	Georg Roth	20S proteasome in critically ill patients
2000-2001	Bernhard Moser	Immunology on haemodialysis patients and transplant recipients

Publications

70 peer reviewed publications in scientific journals, 2 book chapters, 67 invited lectures, 3 patent”

Peer reviewed manuscripts 2003-20078 (original research and reviews)

First, last or corresponding author manuscripts:

Szerafin T, Niederpold T, Mangold A, Hoetzenecker K, Hacker S, Roth G, Lichtenauer M, Dworschak M, Ankersmit HJ. Secretion of Soluble ST2 – Possible Explanation for Systemic Immunosuppression after Heart Surgery. Thorac Cardiovasc Surg. 2008 (ahead of print)

Soleiman A, Lukschal A, Hacker S, Aumayr K, Hoetzenecker K, Lichtenauer M, Moser B, Untersmayr E, Horvat R, Ankersmit HJ. Myocardial lipofuscin-laden lysosomes contain the apoptosis marker caspase-cleaved cytokeratin-18. Eur J Clin Invest. 2008 Oct;38(10):708-12.

Pollreisz A, Assinger A, Hacker S, Hoetzenecker K, Schmid W, Lang G, Wolfsberger M, Steinlechner B, Bielek E, Lalla E, Klepetko W, Volf I, Ankersmit HJ. Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro. Br J Dermatol. 2008 Jun 18. [Epub ahead of print]

Szerafin T, Hoetzenecker K, Hacker S, Horvath A, Pollreisz A, Arpád P, Mangold A, Wluszczak T, Dworschak M, Seitelberger R, Wolner E, Ankersmit HJ. Heat shock proteins 27, 60, 70, 90alpha, and 20S proteasome in on-pump versus off-pump coronary artery bypass graft patients. Ann Thorac Surg. 2008 Jan;85(1):80-7.

Hoetzenecker K, Hacker S, Hoetzenecker W, Sadeghi K, Sachet M, Pollreisz A, Mangold A, Wluszczak T, Bielek E, Muehlbacher F, Klepetko W, Ankersmit HJ. Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro. Eur J Clin Invest. 2007 Dec;37(12):978-86.

Hetz H, Hoetzenecker K, Hacker S, Faybik P, Pollreisz A, Moser B, Roth G, Hoetzenecker W, Lichtenauer M, Klinger M, Krenn CG, Ankersmit HJ. Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration. *J Clin Lab Anal.* 2007;21(5):277-81.

Adlbrecht C, Hoetzenecker K, Posch M, Steiner S, Kopp C, Hacker S, Auer J, Horvath R, Moser B, Roth G, Wolner E, Lang IM, Ankersmit HJ. Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction. *Eur J Clin Invest.* 2007 May;37(5):372-80.

Ankersmit HJ, Hacker S, Hoetzenecker K, Moser B, Wolner E. The impact of hypogammaglobulinemia on infection outcome in patients undergoing ventricular assist device implantation. *J Heart Lung Transplant.* 2006 Nov;25(11):1387-8.

Szerafin T, Horvath A, Moser B, Hacker S, Hoetzenecker K, Steinlechner B, Brunner M, Roth G, Boltz-Nitulescu G, Peterffy A, Wolner E, Ankersmit HJ. Apoptosis-specific activation markers in on- versus off-pump coronary artery bypass graft (CABG) patients. *Clin Lab.* 2006;52(5-6):255-61.

Szerafin T, Brunner M, Horváth A, Szentgyörgyi L, Moser B, Boltz-Nitulescu G, Péterffy A, Hoetzenecker K, Steinlechner B, Wolner E, Ankersmit HJ. Soluble ST2 protein in cardiac surgery: a possible negative feedback loop to prevent uncontrolled inflammatory reactions. *Clin Lab.* 2005;51(11-12):657-63.

Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Hoetzenecker K, Boltz-Nitulescu G, Ankersmit HJ. Heightened levels of circulating 20S proteasome in critically ill patients. *Eur J Clin Invest.* 2005 Jun;35(6):399-403.

Konakci KZ, Bohle B, Blumer R, Hoetzenecker W, Roth G, Moser B, Boltz-Nitulescu G, Gorlitzer M, Klepetko W, Wolner E, Ankersmit HJ. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. *Eur J Clin Invest.* 2005 Jan;35(1):17-23.

Roth GA, Zuckermann A, Klepetko W, Wolner E, Ankersmit HJ, Moser B, Volf I. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. *Transplantation.* 2004 Oct 27;78(8):1238-9

Roth GA, Krenn C, Brunner M, Moser B, Ploder M, Spittler A, Pelinka L, Sautner T, Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients. *Shock.* 2004 Sep;22(3):218-20.

Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E, Spittler A, Sautner T, Bonaros N, Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. *Intensive Care Med.* 2004 Jul;30(7):1468-73.

Ankersmit HJ, Weber T, Auer J, Roth G, Brunner M, Kvas E, Moser B, Spreitzer S,

Lassnig E, Maurer E, Hartl P, Wolner E, Boltz-Nitulescu G, Eber B. Increased serum concentrations of soluble CD95/Fas and caspase 1/ICE in patients with acute angina. *Heart*. 2004 Feb;90(2):151-4.

Roth G, Moser B, Krenn C, Brunner M, Haisjackl M, Almer G, Gerlitz S, Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance. *Biochem Biophys Res Commun*. 2003 Sep 5;308(4):840-6.

Moser B, Roth G, Brunner M, Lilaj T, Deicher R, Wolner E, Kovarik J, Boltz-Nitulescu G, Vychytil A, Ankersmit HJ. Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: a comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. *Biochem Biophys Res Commun*. 2003 Aug 29;308(3):581-5.

Ankersmit HJ, Roth GA, Moser B, Zuckermann A, Brunner M, Rosin C, Buchta C, Bielek E, Schmid W, Jensen-Jarolim E, Wolner E, Boltz-Nitulescu G, Volf I. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. *Am J Transplant*. 2003 Jun;3(6):754-9.

Ankersmit HJ, Roth G, Zuckermann A, Moser B, Obermaier R, Taghavi S, Brunner M, Wieselthaler G, Lanzenberger M, Ullrich R, Laufer G, Grimm M, Wolner E. Rapamycin as rescue therapy in a patient supported by biventricular assist device to heart transplantation with consecutive ongoing rejection. *Am J Transplant*. 2003 Feb;3(2):231-4.

Co-author manuscripts:

Roth GA, Ankersmit HJ, Brown VB, Papapanou PN, Schmidt AM, Lalla E. Porphyromonas gingivalis infection and cell death in human aortic endothelial cells. *FEMS Microbiol Lett*. 2007 Jul;272(1):106-13.

Weigl M, Moritz A, Steinlechner B, Schmatzer I, Mora B, Fakin R, Zimpfer D, Ankersmit HJ, Khazen C, Dworschak M. Neuronal injury after repeated brief cardiac arrests during internal cardioverter defibrillator implantation is associated with deterioration of cognitive function. *Anesth Analg*. 2006 Aug;103(2):403-9.

Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Ankersmit HJ, Fuerst W, Redl H, Roth E, Spittler A. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. *Shock*. 2006 Feb;25(2):129-34.

Hetz H, Bauer M, Lahner D, Faybik P, Winning J, Ankersmit HJ, Bacher A, Krenn CG. Endothelin activation and postoperative renal failure after human liver transplantation. *Liver Transpl*. 2005 Oct;11(10):1201-6.

Gorlitzer M, Ankersmit J, Fiegl N, Meinhart J, Lanzenberger M, Unal K, Dunkler D, Kilo J, Wolner E, Grimm M, Grabenwoeger M. Is the transpulmonary pressure gradient a predictor for mortality after orthotopic cardiac transplantation? *Transpl Int*.

2005 Apr;18(4):390-5.

Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K, Riemer AB, Ankersmit HJ, Scheiner O, Boltz-Nitulescu G, Jensen-Jarolim E. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. *FASEB J.* 2005 Apr;19(6):656-8.

Aigner C, Winkler G, Jaksch P, Ankersmit J, Marta G, Taghavi S, Wisser W, Klepetko W. Size-reduced lung transplantation: an advanced operative strategy to alleviate donor organ shortage. *Transplant Proc.* 2004 Nov;36(9):2801-5.

Taghavi S, Zuckermann A, Ankersmit J, Wieselthaler G, Rajek A, Laufer G, Wolner E, Grimm M. Extracorporeal membrane oxygenation is superior to right ventricular assist device for acute right ventricular failure after heart transplantation. *Ann Thorac Surg.* 2004 Nov;78(5):1644-9.

Ramskogler K, Brunner M, Hertling I, Dvorak A, Kapusta N, Krenn C, Moser B, Roth G, Lesch OM, Ankersmit HJ, Walter H. CDT values are not influenced by epithelial cell apoptosis in chronic alcoholic patients-preliminary results. *Alcohol Clin Exp Res.* 2004 Sep;28(9):1396-8.

Bonaros NE, Kocher A, Dunkler D, Grimm M, Zuckermann A, Ankersmit J, Ehrlich M, Wolner E, Laufer G. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. *Transplantation.* 2004 Mar 27;77(6):890-7.

Taghavi S, Ankersmit J, Zuckermann A, Roth GA, Wieselthaler G, Rajek A, Wolner E, Grimm M. A retrospective analysis of extracorporeal membrane oxygenation versus right ventricular assist device in acute great failure after heart transplantation. *Transplant Proc.* 2003 Nov;35(7):2805-7.

Zuckermann A, Dunkler D, Deviatko E, Bodhjalian A, Czerny M, Ankersmit J, Wolner E, Grimm M. Long-term survival (>10 years) of patients >60 years with induction therapy after cardiac transplantation. *Eur J Cardiothorac Surg.* 2003 Aug;24(2):283-91

Itescu S, Schuster M, Burke E, Ankersmit J, Kocher A, Deng M, John R, Lietz K. Immunobiologic consequences of assist devices. *Cardiol Clin.* 2003 Feb;21(1):119-33

Invited Talks:

Immunologische Vorgänge im Rahmen extrakorporaler Verfahren, Arlberg Refresher Course 2008, Interdisziplinäre Notfall- und Intensivmedizin, Lech-Zug am Arlberg

Immune Dysfunction after open Heart Surgery, Grand Round, Dept. of CT Surgery 2008, Vienna

CMV IVIg Alters Innate and Adaptive Immune function in vitro: "Induction Therapy" Re-visited, Austrotransplant 2007, St. Wolfgang

CMVIg and IVIg induce CD32-mediated platelet aggregation in vitro: implication of therapy induced thrombocytopenia and thrombosis in vivo, Austrotransplant 2007, St. Wolfgang

Elevated levels of interleukin-1 β -converting enzyme and caspase-cleaved cytokeratin-18 (ccCK-18) in acute myocardial infarction, Kardiovaskuläre Forschungstage 2007, Weissensee

Anti-proliferative properties of CMV hyperimmunoglobulin are related to activation induced cell death in vitro: Possible role in tolerance induction, International Society for Heart and Lung Transplantation 27th Annual Meeting 2007, San Francisco

Gigantic coronary fistula: rare finding without clinical symptom, Österreichischer Chirurgenkongress 2007, Graz

Heat shock proteins 27/60/70/90 α and 20S proteasome in on- versus off-pump coronary artery bypass graft patients, Österreichischer Chirurgenkongress 2007, Graz.

CMV Hyperimmunoglobulin evidences anti-proliferative properties and reduces natural occurring cell mediated cytotoxicity in vitro, Österreichischer Chirurgenkongress 2007, Graz

Klinik der Aortenklappenstenose, Fortbildung für Diplomkrankenschwestern, Vienna 4/2007

Targeted Renal Therapy, Grand Round, Vienna 4/2007

Caspase-cleaved cytokeratin 18 and 20S proteasome in liver degeneration, Posterausstellung anlässlich der vfwf-Universitätsvorlesung "Die Medizinische Universität der Zukunft" 2006, Wien

"Die Medizinische Universität der Zukunft" 2006, Wien. Case report: rabbit antithymocyte globulin (rATG) and ECMO bridge as new options in the treatment of giant cell myocarditis, Posterausstellung anlässlich der vfwf-Universitätsvorlesung

Case report: rabbit antithymocyte globulin (rATG) and ECMO bridge as new options in the treatment of giant cell myocarditis, Österreichischer Chirurgenkongress 2006, Wien

CMVIVIg and Immunesuppression, Austrotransplant, Salzburg, 10/2006

Grand Round, Change of Paradigm in Sepsis, Dept. of Surgery, Vienna 6/2006

Folab Chirurgie Grand Round, Xentotransplantation in Cardiac Surgery, Dept. of Surgery, Vienna 5/2006

Morning Round, Apoptosis, Microfilaments and Myocardial Infarction, Dept. of CT Surgery, Vienna 5/2006

Ethik in der Explantation, Salzburg 6/2005

Alpha-Gal on Bioprotheses: Xenograft Immuneresponse in Cardiac Surgery, Seattle 5/2005

Case report: giant cell myocarditis - ECMO and rATG, Austrotransplant 2005, Alpbach

Pooled human Ig and Immunosuppression, Austrotransplant 2005, Alpbach.

Apoptosis specific immunactivation in septic patients, Shock Symposium, Vienna 1/2005

ATG, CD40L and Thrombosis, Austrotransplant, Graz 10/2004

Alpha Galactose on Porcine Valve Protheses: Xenograft Immuneresponse in Cardiac Surgery, Austrotransplant, Graz 10/2004

Endotheliale, zelluläre und immunologische Faktoren in der Sepsis, Universitätsvorlesung für die Univ. Klinik für Anaesthesiologie AKH Wien (morning round) 5/2004

Susceptibility to Programmed Cell Death In T-Lymphocytes From Septic Patients: A Mechanism For Lymphopenia and Th2 Predominance. World Sepsis Kongress, 3/3004

Susceptibility to Programmed Cell Death In T-Lymphocytes From Septic Patients: A Mechanism For Lymphopenia and Th2 Predominance, Wiener Intensivmedizinischen Tage, 4/2004

HIV-Sepsis-VAD-Dialysis Apoptosis and Lymphopenia in patients with chronic antigen contact. 7/2003, Lecture at weekly Labmeeting at Columbia University, AM Schmidt Lab, Columbia University, NY, 7/2003

Aktivierung und Funktionsstörung von Endothelzellen in koronarer Bypasschirurgie:

Vergleich zwischen kardiopulmonalem Bypass und OPCAB. Österreichische Chirurgen, Bregenz, Österreich, 6/2003

T-Zellen Apoptose in Sepsis Patienten: Mechanismen für Lymphopenie. Österreichische Chirurgen, Bregenz, Österreich, 6/2003

Pearls and Pits in Cardiology, Terminale Herzinsuffizienz / Kunstherz / Sarkoidose, Hofburg, Wien, 5/2003

HIV-VAD-Polymer-Dialysis-Sepsis Apoptosis specific T cell activation. Grand Round, Dept. of Immunodermatology, AKH Wien, 3/2003

HIV-VAD-Polymer-Dialysis-Sepsis Apoptosis specific immuneactivation, Ad hoc seminar at the Dept. of Pathophysiology, AKH Wien, 1/2003

Death-Inducing Receptors and Apoptotic Changes in Lymphocytes of Patients with Heart Transplant Vasculopathy, Austrotransplant, Loipersdorf, 11/2002

Transitory Immunologic Response After Implantation Of DeBakey VAD Continuous-Axial-Flow Pump, AST, Washington, 5/2002)

Death Inducing Receptors And Apoptotic Changes In Lymphocytes With Transplant Vasculopathy, AST, Washington, 5/2002)

Long-Term Follow Up Of Three Prospective Randomised Trials Comparing Different Antibody Induction Protocols. Moser, AST, Washington, 5/2002)

Transitory Immunologic Response After Implantation Of DeBakey VAD Continuous-Axial Flow Pump, Washington, ISHLT, 4/2002)

Low Affinity Fc Receptor (CD32) Mediated Platelet Aggregation/Activation In Vitro By AntithymocyteGlobulin: A Possible Explanation For Induction Therapy Mediated Platelet Depletion In Vivo, ISHLT, Washington, 4/2002)

DEHP and Immunosuppression, Int. Cardiovasc. Surg. Symposium Zürs, 2/2002

Rapamun als „Rescue-Therapie“ in einem Patienten mit anhaltender Abstoßung, (Wyeth Seminar- Austrotransplant 2001, Going, Tirol) 11/2001

Low-Affinity FC Receptor (CD32) Mediated Platelet Aggregation in Vitro by Antithymocyteglobuline: A Possible Explanation for Induction Therapy Mediated Platelet Depletion in Vivo. Austrotransplant, Going 11/2001

DHEP (Plastic Softener) in Patients Undergoing Temporary Circulatory Support: Implications in Understanding Immunosuppressive State in Patients Confronted

with Cardiopulmonary Bypass or ECMO, Austrotransplant, Going 11/2001

Invited Lecture to the XIVth Meeting on Heart, and Lung Transplantation and Cardiac Assist Device at the La Pitie Hospital, Paris 10/2001

Pitts and Pearls in Cardiology, Linz, Österreichische Jahrestagung der Kardiologen, Inverted Left Atrial Appendage 5/2001

AST Chicago, USA Low Affinity Fc-Receptor (CD32) Mediated platelet Aggregation/Activation in vitro by Antithymocyte globulin.: A possible explanation for Induction Therapy mediated Platelet Depletion in vivo 5/2001

AST Chicago, USA. Augmented T-Cell Apoptosis in vivo via CD95 and TNF R1 and activation induced T-cell Death by Anti-Thymocyte Antibody Treatment in Stable Cardiac Transplant Recipients (young investigator award) 5/2001

ISHLT Vancouver, Canada. Increased Death Inducing Receptors In Vivo And Activation-Induced T-Cell Death By Anti- Thymocyte Antibody Treatment of Stable Cardiac Transplant Recipients 4/2001

Clinical Round, Intensive Care Unit 13B2, General Hospital Vienna, Lecture pertaining to SIRS, 12/2000

Austrotransplant Schladming, AUT. Aberrant T-Cell Activation Via CD95-CD95L and Activation Induced Cell Death in Peripheral T-Lymphocytes by Poly- and Monoclonal Induction Therapies in Stable Cardiac Transplant Recipients 10/2000

ASAIO New York, NY, USA. Aberrant T Cell Activation via CD95 and Apoptosis in Praedialysis and Dialysis Patients 6/2000

MESOT Beirut, Lebanon, T Cell Activation Via The CD95 Pathway In Heart Transplant Recipients 5/2000

Clinical grand round, General Hospital Vienna. Immune function in HTX recipients and tolerance Induction 5/2000

ISHLT Osaka, Polymeric Biomaterials Induce T Cell Apoptosis And Defects In Cellular Immunity Via Increased Cellular Levels Of NFAT And CD95 Ligand 4/2000

AHA Atlanta. T-Cells Of Heart Transplant Recipients Are Undergoing CD95 (Fas) Mediated Apoptosis: Additional Insights In Transplant Immunobiology 11/99

AHA Atlanta Atlanta. Polymeric Biomaterials Act As Superantigens, Causing T Cell

Apoptosis Via Induction Of CD95L (Fas Ligand) Expression And Defects In Cellular Immunity 11/99

Austrotransplant, St. Wolfgang, Allogene Spenderherzen induzieren CD95 mediierte Apoptose in T-Lymphozyten 10/99

Clinical grand round, General Hospital Vienna. Immunedysfunction in LVAD recipients 8/99

Österreichischer Chirurgen Kongress Linz, Immundefekt nach Implantation von LVAD Systemen 8/99

ISHLT San Francisco T Cell Activation In Left Ventricular Assist Device (LVAD) Recipients Occurs Via A CD95-Dependent Pathway, And Results In Loss Of Th1 Cells And High Levels Of Circulating IL-10 4/99

ISHLT San Francisco T Cell Apoptosis And Defects In Cellular Immunity Induced By Exposure To Biomaterials: Implications For Left Ventricular Assist Device (LVAD) Implantation 4/99

AHA Featured Research Session Dallas T Cell Mediated Defects And B Cell Hyperreactivity In LVAD Recipients Are Related To Loss Of Th1 Cytokine Production 11/98

Shumway Lecture Columbia University New York. T Cell Activation In Left Ventricular Assist Device (LVAD) Recipients Occurs Via A CD95-Dependent Pathway 10/98

Finalist Residents Research Competition Columbia University New York Defective T Cell Activation In Vivo And In Vitro Following Exposure To Left Ventricular Assist Device Implantation 7/98

ISHLT Chicago Defective T Cell Activation in vivo and in vitro Following Exposure To Left Ventricular Assist Device Implantation 4/98

ISHLT Chicago Recipients Of Left Ventricular Assist Devices Are At Increased Risk For Developing Opportunistic Fungal Infections 4/98